Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. SPY
2. AVAV
3. NVDA
4. EOSE
5. NKE
6. MU
7. DLR
8. AAPL
9. TSLA
10. VSH

Go back to Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 4:06 PM EST

Collaboration will combine Moderna's mRNA technology with CytomX's Probody Platform to generate and develop therapeutics for oncology and non-oncology conditions

CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments

CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational... More